Broadly neutralizing antibodies derived from the earliest COVID-19 convalescents protect mice from SARS-CoV-2 variants challenge

Coronavirus disease 2019 (COVID-19) was first reported three years ago, when a group of individuals were infected with the original SARS-CoV-2 strain, based on which vaccines were developed. Here, we develop six human monoclonal antibodies (mAbs) from two elite convalescents in Wuhan and show that t...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Qianyun, Zhao, Haiyan, Li, Zhiqiang, Zhang, Zhen, Huang, Rui, Gu, Mengxue, Zhuang, Ke, Xiong, Qing, Chen, Xianying, Yu, Weiyi, Qian, Shengnan, Zhang, Yuzhen, Tan, Xue, Zhang, Muyi, Yu, Feiyang, Guo, Ming, Huang, Zhixiang, Wang, Xin, Xiang, Wenjie, Wu, Bihao, Mei, Fanghua, Cai, Kun, Zhou, Limin, Zhou, Li, Wu, Ying, Yan, Huan, Cao, Sheng, Lan, Ke, Chen, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499932/
https://www.ncbi.nlm.nih.gov/pubmed/37704615
http://dx.doi.org/10.1038/s41392-023-01615-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499932/
https://www.ncbi.nlm.nih.gov/pubmed/37704615
http://dx.doi.org/10.1038/s41392-023-01615-0

Ejemplares similares